Old Web
English
Sign In
Acemap
>
authorDetail
>
Rafaela López
Rafaela López
Medicine
Delayed toxicity
Refractory
Rituximab
Response rate (survey)
3
Papers
52
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
PRESCRIPTION PATTERNS AND OUTCOMES OF FIRST-LINE THERAPY FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA REAL-LIFE PATIENTS ACCORDING TO AGE: A RETROSPECTIVE ANALYSIS OF THE 2012-2016 PERIOD: PB2144
2019
María J Cejalvo
Anna Sureda
Eva González
J. Vázquez Álvarez
R. Garcia
Angel Ramírez
E. Pérez-Persona
Eugenia Abella
S Garzón
A. Garcia
Isidro Jarque
Marta González
Antonia Sampol
Cristina Motlló
Josep Martí
M. Alcalá
R. Duro
Yolanda González
Sastre Jl
Josep Sarrà
G. Lostaunau
Rafaela López
J de la Rubia
Show All
Source
Cite
Save
Citations (0)
Efficacy and safety of rituximab in adult patients with idiopathic relapsing or refractory thrombotic thrombocytopenic purpura: Results of a Spanish multicenter study
2010
Transfusion and Apheresis Science
Javier de la Rubia
Federico Moscardó
María J Gómez
Ramon Guardia
Pilar Rodríguez
Ana Sebrango
Concepción Zamora
Guillermo Deben
Rosa Goterris
Rafaela López
Francisco Peña
Misericordia Pujol
Antonio Vidaller
Julio del Río-Garma
Miguel A. Sanz
Show All
Source
Cite
Save
Citations (52)
Efficacy and Safety of Rituximab in Adult Patients with Idiopathic Relapsed or Refractory Thrombotic Thrombocytopenic Purpura (TTP). Results of a Spanish Multicenter Study.
2008
Blood
Javi er de la Rubia
Federico Moscardó
María J Gómez
Ramon Guardia
Pilar Rodríguez
Ana Sebrango
Concha Zamora
Guillermo Deben
Rosa Goterri
Rafaela López
Francisco Peña
Micola Pujol
Show All
Source
Cite
Save
Citations (0)
1